{"id":"another-available-a1pi","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL58301","moleculeType":"Small molecule","molecularWeight":"353.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alpha-1 antitrypsin is a protease inhibitor that protects lung tissue from degradation by neutrophil elastase. In alpha-1 antitrypsin deficiency, insufficient levels of this protective protein lead to unopposed elastase activity and progressive emphysema. Intravenous A1PI augmentation therapy restores circulating and lung levels of the inhibitor, slowing or halting lung function decline.","oneSentence":"This drug replaces deficient alpha-1 protease inhibitor (A1PI) protein to prevent progressive lung damage in patients with alpha-1 antitrypsin deficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:54.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease"}]},"trialDetails":[{"nctId":"NCT05466747","phase":"PHASE4","title":"A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2024-01-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Alpha1-Antitrypsin Deficiency","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alpha1-PI","Alpha1-Proteinase Inhibitor (Human)"],"phase":"marketed","status":"active","brandName":"Another Available A1PI","genericName":"Another Available A1PI","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"Another Available A1PI is a small molecule intervention being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and Alpha1-Antitrypsin Deficiency. It is being investigated in a clinical study, NCT05466747, as part of a study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}